From methylene blue to chloroquine: a brief review of the development of an antimalarial therapy

@article{Krafts2012FromMB,
  title={From methylene blue to chloroquine: a brief review of the development of an antimalarial therapy},
  author={Kristine P Krafts and Ernst Hempelmann and Agnieszka Sk{\'o}rska-Stania},
  journal={Parasitology Research},
  year={2012},
  volume={111},
  pages={1-6}
}
Malarial treatment is widely and readily available today. However, there was a time in the not-so-distant past when malaria was a deadly disease with no known cause or cure. In this article, we trace the origins of an antimalarial therapy from the discovery of the nature of the malarial parasite through the development of chloroquine. We dedicate this article to Johann “Hans” Andersag, the scientist who developed chloroquine, on the 110th anniversary of his birth, 16 February 1902. 
Current Antimalarial Therapies and Advances in the Development of Semi-Synthetic Artemisinin Derivatives.
TLDR
This review describes the drugs based on artemisinin and its derivatives, including hybrid derivatives and dimers, trimers and tetramers that contain an endoperoxide bridge, of extreme importance for the discovery of new drugs to treat malaria.
Efficacy and safety of methylene blue in the treatment of malaria: a systematic review
TLDR
Adding MB to ACT could be a valuable approach for the prevention of resistance development and for transmission reduction in control and elimination programs.
Chloroquine Related to Malaria and its Promising Applications for Covid-19 Treatment
TLDR
Chloroquine seems to have potential antiviral properties that may be useful in the treatment of these severe acute forms of COVID-19 associated with Azithromycin, Nevertheless, its indication must include ECG monitoring due to the risk of prolongation of QT interval, leading to sudden cardiac death.
Recent Advances in Antimalarial Drug Discovery — Challenges and Opportunities
TLDR
This chapter will provide an integrated overview on the challenges and opportunities in malaria drug discovery with more emphasis on synthesis of peroxidic antimalarials.
In vivo and in vitro antimalarial effect and toxicological evaluation of the chloroquine analogue PQUI08001/06
TLDR
It is observed that PQUI08001/06 treatment reduces parasitemia of both chloroquine-resistant and -sensitive strains of Plasmodium falciparum in vitro and P. berghei in vivo.
Antimalarial chloroquine indicated for viral infections: myth ou hope?
TLDR
Chloroquine seems to have potential antivirotic properties that may be useful in the treatment of the grave acute forms of COVID-19 associated with Azithromycin, but its indication must include ECG monitoring due to the risk of cardiac QT prolongation able to cause sudden deaths.
Artemisinin‐derived antimalarial endoperoxides from bench‐side to bed‐side: Chronological advancements and future challenges
According to WHO World Malaria Report (2018), nearly 219 million new cases of malaria occurred and a total no. of 435 000 people died in 2017 due to this infectious disease. This is due to the rapid
PharmGKB summary: methylene blue pathway
TLDR
The pharmacodynamics of methylene blue in the context of methemoglobinemia treatment and the pathways surrounding this are focused on, due to known pharmacogenetic associations that relate to these pathways.
Chloroquine and Hydroxychloroquine for the Treatment of COVID-19 patients: What Every Clinician Should Know
TLDR
The up-to-date information on the efficacy and safety of CQ and HCQ for practitioners in the treatment of COVID-19 patents is reviewed.